Cannabinoid CB1 receptor agonist treatmentin severe chronic anorexia nervosa

Center for Spiseforstyrrelse, Endokrinologisk Afdeling M, Odense Universitetshospital0 个研究点目标入组 22 人开始时间: 2008年3月12日最近更新: 2021年6月7日

试验速览

暂无简介。

•1Patients under treatment for AN.
•2Patients attending ambulatory treatment, which are not expected to be admitted at the hospital with AN-related pathology or discharged during the study period.
•3Patients admitted to Department of Endocrinology M or Psychiatric department P which are not expected to be discharged during the study period.
•4Age over 18.
•5Duration of the disease over 5 years.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1Patients under compulsory treatment or suffering of mania, schizophrenia or primary depression.
•2Patients with any medical or psychiatric event related or not related to the underlying eating disorder which requires prolonged admission to the hospital during the study.
•3Patients with unstable heart disease (relevant changes in medication prior or during the study) and limitation of activity (not comfortable with more than moderate exertion / at rest).
•4Patients not attending to the weekly controls.
•5If other severe adverse events (SAE) / drug reactions (SADR) are suspected.
•6Patients actually having or having a history of alcohol, cannabis, opioids or central stimulating drugs abuse.
•7Patients with known allergy to dronabinol or sesam oil.
•8Fertile, menstruating women not using safe contraception*.
•9Pregnancy.
•* - Patients with chronic AN have per definition amenorrhea and seldom vita sexualis.

发起方

Center for Spiseforstyrrelse, Endokrinologisk Afdeling M, Odense Universitetshospital